Top Markets
Coin of the day
Cell Source, Inc. Cell Source, Inc.

Cell Source, Inc.

CLCS
Clasificación en acciones #28220
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based... Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Precio por acción
$0.4
Última sincronización: 2026-10-02
Capitalización bursátil
$27.18M
Cambio (1 día)
-14.88%
Cambio (1 año)
8.11%
País
US
Comercio Cell Source, Inc. (CLCS)

Categoría

Ganancias de Cell Source, Inc. (CLCS)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Cell Source, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Cell Source, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$-3.09B -
US
$-4.02B -
AU
$1.95B -
NL
- -
CH